Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

OBJECTIVE: To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR). METHODS: PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Tundia, Namita, Bergman, Martin, Ostor, Andrew, Durez, Patrick, Song, In-Ho, Enejosa, Jeffrey, Schlacher, Casey, Song, Yan, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645276/
https://www.ncbi.nlm.nih.gov/pubmed/33590829
http://dx.doi.org/10.1093/rheumatology/keab158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645276/
https://www.ncbi.nlm.nih.gov/pubmed/33590829
http://dx.doi.org/10.1093/rheumatology/keab158

Ejemplares similares